DDInter790 DDInter1660
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Semaglutide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} (Compound) resembles {v} (Compound) Metolazone
Metolazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) binds {v} (Gene) CA2
CA2 {u} (Gene) is bound by {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide {u} (Compound) causes {v} (Side Effect) Abdominal distension
Abdominal distension {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Semaglutide
Furosemide {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) binds CA2 (Gene) and CA2 (Gene) is bound by Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Furosemide (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Semaglutide
Furosemide (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide